menu
    • menu

    Company profile for Vergent Bioscience

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    The company is developing tumor-targeted agents that enhance surgeons’ ability to visualize tumors intraoperatively, making cancer surgery more successful for them and their patients. Bringing together an innovative imaging agent, a commitment to rigorous science, and a world-class leadership team, Vergent Bioscience is positioned to become the global leader in intraoperative cancer surgery.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Vergent BioscienceUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    5810 W 78th St, Ste 222 Minneapolis, MN 55439
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.vergentbio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Vergent Bioscience Initiates Phase 3 VISUALIZE 2 Pivotal Study
    Vergent Bioscience Initiates Phase 3 VISUALIZE 2 Pivotal Study

    17 Mar 2026

    // BUSSINESSWIRE

    https://www.businesswire.com/news/home/20260317277443/en/Vergent-Bioscience-Initiates-Phase-3-VISUALIZE-2-Pivotal-Study-of-Abenacianine-VGT-309-for-Tumor-Visualization-During-Lung-Cancer-Surgery

    BUSSINESSWIRE
    17 Mar 2026
    Share Share
    Vergent Shows Abenacianine Boosts Tumor Visibility in Surgery
    Vergent Shows Abenacianine Boosts Tumor Visibility in Surgery

    22 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250522931576/en/Vergent-Bioscience-Presents-Phase-2B-VISUALIZE-Results-Demonstrating-Abenacianine-for-Injection-VGT-309-with-Intraoperative-Molecular-Imaging-Improved-Tumor-Visualization-During-Lung-Surgery

    BUSINESSWIRE
    22 May 2025
    Share Share
    Vergent Bioscience to Present Abenacianine Data at 2025 ASCO Meet
    Vergent Bioscience to Present Abenacianine Data at 2025 ASCO Meet

    08 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250508457679/en/Vergent-Bioscience-to-Present-Data-on-Abenacianine-for-Injection-VGT-309-at-2025-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting

    BUSINESSWIRE
    08 May 2025
    Share Share
    Vergent Bio Completes Phase 2 Trial Enrollment for Abenacianine
    Vergent Bio Completes Phase 2 Trial Enrollment for Abenacianine

    13 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241113834604/en

    BUSINESSWIRE
    13 Nov 2024
    Share Share
    Vergent's VGT-309 Shows Promise In Lung Tumor Visualization
    Vergent's VGT-309 Shows Promise In Lung Tumor Visualization

    18 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240718054254/en

    BUSINESSWIRE
    18 Jul 2024
    Share Share
    Vergent Initiates Phase 2 Study Evaluating VGT-309
    Vergent Initiates Phase 2 Study Evaluating VGT-309

    13 Dec 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231213727404/en

    BUSINESSWIRE
    13 Dec 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search